BDBM238259 US10336741, Example 71::US10882855, Example 71::US9394250, 71::US9585881, Example 71

SMILES COC(=O)Nc1ccc(cc1)-c1[nH]c(nc1Cl)[C@@H]1C[C@@H](CN1C(=O)C1CCN(CC1)C(N)=N)C1CCN(CC1)S(C)(=O)=O

InChI Key InChIKey=HOTFNPNTKCEFJL-UHFFFAOYSA-N

Data  12 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 12 hits for monomerid = 238259   

TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238259(US9394250, 71 | US9585881, Example 71 | US10336741...)
Affinity DataIC50: 2.20nMAssay Description:Human Factor XIa (Haematologic Technologies Inc.) activity was measured at an enzyme concentration of 0.1 U/mL in 150 mM NaCl, 5 mM KCl, 1 mg/mL PEG6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/17/2017
Entry Details
Go to US Patent

TargetProthrombin(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238259(US9394250, 71 | US9585881, Example 71 | US10336741...)
Affinity DataIC50: 9.40E+4nMAssay Description:Human Factor Xa (American Diagnostica Inc.) and human thrombin (Sigma) activities were measured at the enzyme concentrations of 0.18 U/mL and 0.12 U/...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/17/2017
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238259(US9394250, 71 | US9585881, Example 71 | US10336741...)
Affinity DataIC50: 1.00E+5nMAssay Description:Human Factor Xa (American Diagnostica Inc.) and human thrombin (Sigma) activities were measured at the enzyme concentrations of 0.18 U/mL and 0.12 U/...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/17/2017
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238259(US9394250, 71 | US9585881, Example 71 | US10336741...)
Affinity DataIC50: 2.20nMAssay Description:Human Factor XIa (Haematologic Technologies Inc.) activity was measured at an enzyme concentration of 0.1 U/mL in 150 mM NaCl, 5 mM KCl, 1 mg/mL PEG6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
Go to US Patent

TargetProthrombin(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238259(US9394250, 71 | US9585881, Example 71 | US10336741...)
Affinity DataIC50: 9.40E+4nMAssay Description:Human Factor Xa (American Diagnostica Inc.) and human thrombin (Sigma) activities were measured at the enzyme concentrations of 0.18 U/mL and 0.12 U/...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238259(US9394250, 71 | US9585881, Example 71 | US10336741...)
Affinity DataIC50: 1.00E+5nMAssay Description:Human Factor Xa (American Diagnostica Inc.) and human thrombin (Sigma) activities were measured at the enzyme concentrations of 0.18 U/mL and 0.12 U/...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238259(US9394250, 71 | US9585881, Example 71 | US10336741...)
Affinity DataIC50: 2.20nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetProthrombin(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238259(US9394250, 71 | US9585881, Example 71 | US10336741...)
Affinity DataIC50: 9.40E+4nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238259(US9394250, 71 | US9585881, Example 71 | US10336741...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238259(US9394250, 71 | US9585881, Example 71 | US10336741...)
Affinity DataIC50: 2.20nMAssay Description:Human Factor XIa (Haematologic Technologies Inc.) activity was measured at an enzyme concentration of 0.1 U/mL in 150 mM NaCl, 5 mM KCl, 1 mg/mL PEG6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
Go to US Patent

TargetProthrombin(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238259(US9394250, 71 | US9585881, Example 71 | US10336741...)
Affinity DataIC50: 9.40E+4nMAssay Description:Human Factor Xa (American Diagnostica Inc.) and human thrombin (Sigma) activities were measured at the enzyme concentrations of 0.18 U/mL and 0.12 U/...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238259(US9394250, 71 | US9585881, Example 71 | US10336741...)
Affinity DataIC50: 1.00E+5nMAssay Description:Human Factor Xa (American Diagnostica Inc.) and human thrombin (Sigma) activities were measured at the enzyme concentrations of 0.18 U/mL and 0.12 U/...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
Go to US Patent